ScandiDos AB (SE:SDOS)
:SDOS
Want to see SE:SDOS full AI Analyst Report?
Top Page
ScandiDos AB
(SDOS)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.82
▼(-28.87% Downside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance (persistent losses, mostly negative free cash flow, and a concerning 2026 gross profit deterioration) and a clearly bearish technical setup (price below key moving averages and negative MACD). The main offset is a conservative balance sheet with essentially no debt, while valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Conservative balance sheet
Zero or negligible debt provides durable financial flexibility for a small medtech firm. It lowers default risk, supports continued R&D and regulatory compliance spend, and gives management time to fix operating issues without immediate refinancing pressure.
Negative Factors
Persistent losses and cash burn
Sustained net losses and predominantly negative free cash flow erode equity and limit reinvestment capacity. Over 2–6 months this constrains product development, clinical support expansion, and marketing, raising execution risk unless cash consumption is arrested or new funding secured.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero or negligible debt provides durable financial flexibility for a small medtech firm. It lowers default risk, supports continued R&D and regulatory compliance spend, and gives management time to fix operating issues without immediate refinancing pressure.
Read all positive factors
ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr48.17M
Dividend YieldN/A
Average Volume (3M)69.69K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-12.32%
EPS Growth-1156.14%
CountrySE
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding57,011,086
10 Day Avg. Volume66,689
30 Day Avg. Volume69,692
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)1.34
Price to Sales (P/S)3.95
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ScandiDos AB Business Overview & Revenue Model
Company Description
ScandiDos AB (publ), established in Uppsala, Sweden, in 2005, develops advanced measurement systems and software specifically for the quality assurance (QA) and validation demands of innovative medical treatments utilized in clinics worldwide. The...
How the Company Makes Money
ScandiDos generates revenue primarily by selling radiation therapy QA products and related services to hospitals, cancer centers, and radiotherapy clinics. Key revenue streams typically include (1) product sales of QA hardware and systems used to ...
ScandiDos AB Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2023 | Apr 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.22M | 60.43M | 60.43M | 61.55M | 57.68M |
| Gross Profit | -2.71M | 47.55M | 47.55M | 52.95M | 47.92M |
| EBITDA | -439.00K | -5.79M | -13.36M | -8.26M | -7.11M |
| Net Income | -3.44M | -14.65M | -14.65M | -9.12M | -7.34M |
Balance Sheet | |||||
| Total Assets | 65.97M | 73.38M | 81.47M | 72.42M | 66.19M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 10.06M | 1.53M | 3.55M | 6.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 24.31M | 28.40M | 37.19M | 30.77M | 28.99M |
| Stockholders Equity | 41.66M | 44.98M | 44.29M | 41.65M | 37.20M |
Cash Flow | |||||
| Free Cash Flow | -2.92M | -2.71M | -1.46M | -16.31M | -2.31M |
| Operating Cash Flow | -2.92M | 230.00K | 1.49M | -11.90M | 2.39M |
| Investing Cash Flow | -3.87M | -2.94M | -2.94M | -4.37M | -4.77M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 12.33M | -83.00K |
ScandiDos AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:SDOS
ScandiDos AB
0.84
-0.51
-37.69%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.27
0.07
36.50%
DE:2OK
SpectraCure AB
0.01
0.00
0.00%
DE:24C
C-Rad AB Class B
3.27
0.18
5.69%
DE:LUR
Luxbright AB
0.01
-0.05
-83.33%
DE:MN2
Mentice AB
1.19
-0.18
-13.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.